Drug Conjugates

The best of two worlds.

Since the FDA approved the first antibody-drug conjugate for treating Acute Myeloid Leukemia (AML) in 2000, it paved the way for a world of possibilities for drug development. Traditionally developed for cancer treatment, applications such as autoimmune, neurological, cardiovascular, and infectious diseases are actively explored. Drug conjugates are varied, from antibodies conjugated to small molecules or oligos to small molecule-targeting ligands conjugated with cytotoxic drugs. The development of each type of conjugate comes with unique challenges. KreaMedica’s team of experts can help you design a preclinical program and navigate the challenges inherent to your compound to satisfy regulatory requirements.

Unique Challenges within a Drug Conjugate Preclinical Program Development

Drug conjugates may have toxicity or off-target effects that differ from the expected profile of the therapeutic drug, including the potential for an immunomodulating effect.
Generally composed of three portions: a targeting ligand, a linker, and a drug, each representing a potential for toxicity and off-target effects that should be monitored.
Differences in the ratio of drug molecules per targeting ligand can lead to complicated pharmacokinetics.
Linker cleavage and drug release often begin non-specifically once the drug conjugate is administered.
Species selection for preclinical studies should consider the drug’s mechanism of action, ligand biology, and linker chemistry.

KreaMedica’s Solutions

KreaMedica’s team of expert toxicologists and scientists can help you design a preclinical program tailored to your drug conjugate’s specific properties.
We have the assay development expertise to help you select the appropriate assays for quantifying your drug conjugate, its metabolites, and its components in your preclinical studies.
Our team can guide you in the selection of the relevant rodent and non-rodent species for your preclinical studies.
Our network of service providers includes everything from early discovery and preclinical development to complex pharmacokinetic and toxicokinetic modeling and more.
With a program manager and a preclinical scientist assigned to your studies, we help you coordinate your program’s activities to ensure your milestones are met.

Truth in Numbers

110+

Development Programs

70+

Sponsors Who Trust Us

73+

Years Combined
Industry Experience

Testimonials

Don’t take our word for it.

James L. Ellis, Ph.D.
Nocion Therapeutics, Inc., Chief Scientific Officer

They provided valuable insights and recommendations while seamlessly integrating into our team.

I have had the pleasure of working with KreaMedica on several programs. They proactively identified and addressed issues and provided regular updates to ensure everyone was on the same page. Their attention to detail and willingness to take ownership of the project’s success makes them invaluable partners. They are great to work with, and I would highly recommend them to anyone looking for a drug development partner.

Brian Jones
Respirion Pharmaceuticals, Chief Operating Officer

KreaMedica was an essential complement to our virtual team.

They supplemented and filled in gaps in our internal network and worked well with our advisors. They truly wanted to contribute to and be part of the project’s success. I highly recommend Claude, Poulomee, and Rudi as reliable partners for planning and executing toxicological and bioanalytical projects.

Ron Wolff
RK Wolff Safety Consulting Inc., Principal

The combination of all their perspectives made a tremendous difference.

I have worked with KreaMedica for many years, and I must credit them for the team’s talent, professionalism, and chemistry. That doesn’t happen by accident. As a consultant, I rely on them as the first line to monitor studies and provide proactive solutions when required.

Contact Us

Start Your Biotech Journey

Learn More